Enbrel® (etanercept)

Overview | Product information | Accredo services | Contact team

Rheumatoid arthritis (RA)
Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. Enbrel can be initiated in combination with methotrexate (MTX) or used alone.

Plaque psoriasis
Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Polyarticular juvenile idiopathic arthritis (JIA)
Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

Psoriatic arthritis
Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Ankylosing spondylitis (AS)
Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

For more information, please visit Enbrel.com, or download the full prescribing information.